CUE – Cue Biopharma Inc
CUE
$18.76Name : Cue Biopharma, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $136,280,416.00
EPSttm : -29.59
Cue Biopharma, Inc.
$18.76
CUE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
13.59
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-16.61
EPS This/Next Y
17.57
Price
19
Target Price
88
Analyst Recom
1
Performance Q
-38.33
Upside
-5,137.3%
Beta
2.81
Ticker: CUE
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | CUE | 24.5 | N/A | N/A | 0 |
| 2026-10-13 | CUE | 19.54 | N/A | N/A | 0 |
| 2026-10-14 | CUE | 18.33 | N/A | N/A | 0 |
| 2026-10-15 | CUE | 18.9 | N/A | N/A | 0 |
| 2026-10-16 | CUE | 16.71 | 0.06 | 0.00 | 383 |
| 2026-10-19 | CUE | 16.1 | 0.06 | 0.00 | 383 |
| 2026-10-20 | CUE | 17.12 | 0.06 | 0.00 | 383 |
| 2026-10-21 | CUE | 19.07 | 0.06 | 0.00 | 383 |
| 2026-10-22 | CUE | 18.83 | 0.06 | 0.00 | 383 |
| 2026-10-23 | CUE | 18.43 | 0.06 | 0.00 | 383 |
| 2026-10-26 | CUE | 18.42 | N/A | N/A | 0 |
| 2026-10-27 | CUE | 18.09 | N/A | N/A | 0 |
| 2026-10-28 | CUE | 21.31 | N/A | N/A | 0 |
| 2026-10-29 | CUE | 21.11 | N/A | N/A | 0 |
| 2026-10-30 | CUE | 20.81 | N/A | N/A | 0 |
| 2026-11-02 | CUE | 19.11 | N/A | N/A | 0 |
| 2026-11-03 | CUE | 20.5 | N/A | N/A | 0 |
| 2026-11-04 | CUE | 19.72 | N/A | N/A | 0 |
| 2026-11-05 | CUE | 18.05 | N/A | N/A | 0 |
| 2026-11-06 | CUE | 18.58 | N/A | N/A | 0 |
| 2026-11-09 | CUE | 20.715 | N/A | N/A | 0 |
| 2026-11-10 | CUE | 19.17 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | CUE | 24.76 | - | - | -25.01 |
| 2026-10-13 | CUE | 19.50 | - | - | -25.01 |
| 2026-10-14 | CUE | 18.38 | - | - | -25.01 |
| 2026-10-15 | CUE | 18.78 | - | - | -25.01 |
| 2026-10-16 | CUE | 16.79 | - | - | -25.01 |
| 2026-10-19 | CUE | 16.10 | - | - | -25.01 |
| 2026-10-20 | CUE | 16.10 | - | - | -25.01 |
| 2026-10-21 | CUE | 17.18 | - | - | -25.01 |
| 2026-10-22 | CUE | 18.85 | - | - | -25.01 |
| 2026-10-23 | CUE | 18.59 | - | - | -25.01 |
| 2026-10-26 | CUE | 18.38 | - | - | -25.01 |
| 2026-10-27 | CUE | 18.20 | - | - | -25.01 |
| 2026-10-28 | CUE | 21.26 | - | - | -25.01 |
| 2026-10-29 | CUE | 21.40 | - | - | -25.01 |
| 2026-10-30 | CUE | 20.58 | - | - | -25.01 |
| 2026-11-02 | CUE | 19.22 | - | - | -25.01 |
| 2026-11-03 | CUE | 20.99 | - | - | -25.01 |
| 2026-11-04 | CUE | 19.79 | - | - | -25.01 |
| 2026-11-05 | CUE | 18.01 | - | - | -25.01 |
| 2026-11-06 | CUE | 18.58 | - | - | -25.01 |
| 2026-11-09 | CUE | 20.40 | - | - | -25.01 |
| 2026-11-10 | CUE | 19.00 | - | - | -25.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | CUE | -6.59 | 19.30 | 11.27 |
| 2026-10-13 | CUE | -6.59 | 19.30 | 12.09 |
| 2026-10-14 | CUE | -4.78 | 19.30 | 12.09 |
| 2026-10-15 | CUE | -5.65 | 19.30 | 12.09 |
| 2026-10-16 | CUE | -5.65 | 19.30 | 12.09 |
| 2026-10-19 | CUE | -5.65 | 20.59 | 12.04 |
| 2026-10-20 | CUE | -5.70 | 20.59 | 12.04 |
| 2026-10-21 | CUE | -5.70 | 20.59 | 12.04 |
| 2026-10-22 | CUE | -5.70 | 20.59 | 12.04 |
| 2026-10-23 | CUE | -5.70 | 20.59 | 12.04 |
| 2026-10-26 | CUE | -5.70 | 20.72 | 12.04 |
| 2026-10-27 | CUE | -5.70 | 20.72 | 13.59 |
| 2026-10-28 | CUE | -5.70 | 20.72 | 13.59 |
| 2026-10-29 | CUE | -5.70 | 20.72 | 13.59 |
| 2026-10-30 | CUE | -5.70 | 20.72 | 13.59 |
| 2026-11-02 | CUE | -5.70 | 20.66 | 13.59 |
| 2026-11-03 | CUE | -5.70 | 20.66 | 13.59 |
| 2026-11-05 | CUE | -5.70 | 20.66 | 13.59 |
| 2026-11-06 | CUE | -5.70 | 20.66 | 13.59 |
| 2026-11-09 | CUE | -5.70 | 20.66 | 13.59 |
| 2026-11-10 | CUE | -5.70 | 20.66 | 13.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-2.24
Avg. EPS Est. Next Quarter
-1.76
Insider Transactions
-5.7
Institutional Transactions
20.66
Beta
2.81
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
12
Growth Score
36
Sentiment Score
49
Actual DrawDown %
96.6
Max Drawdown 5-Year %
-99
Target Price
88
P/E
Forward P/E
PEG
P/S
3.62
P/B
42.47
P/Free Cash Flow
EPS
-27
Average EPS Est. Cur. Y
-25.01
EPS Next Y. (Est.)
-7.44
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-435.83
Relative Volume
0.51
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
-3.56
EBIT Estimation
◆
CUE
Healthcare
$18.76
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
2/20
Pullback
17/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
43.7
Range 1M
25.7%
Sup Dist
2.3%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
1/25
Growth
13/30
Estimates
0/20
Inst/Vol
5/15
Options
0/10
EPS Yr
-197.7%
EPS NY
70.2%
52W%
35.3%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+369.1% upside
Quality
6/30
Valuation
16/30
Growth
8/25
Stability
2/10
LT Trend
0/5
Upside
+369.1%
Quality
12
Click a card to see score breakdown
Full Analysis →
CUE — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 29
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
CUE
Latest News
—
Caricamento notizie per CUE…
stock quote shares CUE – Cue Biopharma Inc Stock Price stock today
news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CUE – Cue Biopharma Inc yahoo finance google finance
stock history CUE – Cue Biopharma Inc invest stock market
stock prices CUE premarket after hours
ticker CUE fair value insiders trading